每周脂质体紫杉醇联合替吉奥胶囊治疗晚期胃癌的临床疗效及安全性

目的 观察脂质体紫杉醇每周联合替吉奥胶囊治疗晚期胃癌的疗效和不良反应，评价该方案的耐受性。方法 30例晚期胃癌患者接受脂质体紫杉醇每周方案联合替吉奥胶囊治疗：脂质体紫杉醇60 mg/m²，d1，8，15 ，22，替吉奥胶囊60 mg d1～28，每6周为1疗程。每疗程评价疗效及不良反应。结果所有的患者中位治疗疗程为2个（1～6个）。30例患者中CR 0例，PR 8例，SD 16例，PD 6例，有效率为26.7% ，疾病控制率为80％。中位PFS时间为6.5月，中位生存时间为13.5月。主要的不良反应包括骨髓抑制、乏力和消化 道反应。Ⅲ～Ⅳ级毒性为中性粒细胞减少4例（13.3%），乏力1例（3.3%）。结论 脂质体紫杉醇每周联合替吉奥胶囊治疗晚期胃癌的近期疗效好，耐受性好，可推荐作为晚期胃癌的治疗选择。

Efficacy and Safety of Weekly Liposome-paclitaxel Combined with Tegafur on Metastatic Gastric Cancer

Objective To evaluate the efficacy and safety of weekly liposome- paclitaxel combination with tegafur against gastric cancer.Methods Thirty metastatic gastric cancer patients received 42-day cycle of liposome- paclitaxel on day 1，8，15，22 and tegafur on day 1 to 28. Response rate and toxicity were evaluated every cycle.Results The median number of treatment was 2 cycles (1-6 cycles). The overall response rate was 26.7%, the disease controlled rate was 80%. The median progression free survival time was 6.5months. The median overall survival time was 13.5 months. The main treatment related toxicities were hematologic toxicity, fatigue, and gastrointestinal reaction. Grade Ⅲ-Ⅳ toxicity included neutropenia (13.3%) and fatigue (3.3%).Conclusion Combination therapy of weekly liposome-paclitaxel and tegafur is an effective and welltolerated regimen in metastatic gastric cancer.